Han Zhaodi, Guo Linling, Yu Xinyue, Guo Huimin, Deng Xiaoying, Yu Jiayu, Deng Xueyang, Xu Fengguo, Zhang Zunjian, Huang Yin
Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing, 210009, China.
Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Ministry of Education, Nanjing, 210009, China; Department of Pharmaceutical Analysis, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
J Ethnopharmacol. 2022 Apr 6;287:114967. doi: 10.1016/j.jep.2022.114967. Epub 2022 Jan 4.
Astragali Radix (AR) is a popular traditional Chinese medicine that has been used for more than 2000 years. It is a well-known tonic for weak people with chronic diseases, such as heart failure and cerebral ischemia. Previous studies have reported that AR could support the "weak heart" of cancer patients who suffered from doxorubicin (DOX)-induced cardiotoxicity (DIC). However, the underlying mechanism remains unclear.
This study aimed to uncover the critical pathways and molecular determinants for AR against DIC by fully characterizing the network-based relationship.
We integrated ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) profiling, database and literature searching, and the human protein-protein interactome to discover the specific network module associated with AR against DIC. To validate the network-based findings, a low-dose, long-term DIC mouse model and rat cardiomyoblast H9c2 cells were employed. The levels of potential key metabolites and proteins in hearts and cells were quantified by the LC-MS/MS targeted analysis and western blotting, respectively.
We constructed one of the most comprehensive AR component-target network described to date, which included 730 interactions connecting 64 unique components and 359 unique targets. Relying on the network-based evaluation, we identified fatty acid metabolism as a putative critical pathway and peroxisome proliferator-activated receptors (PPARα and PPARγ) as potential molecular determinants. We then confirmed that DOX caused the accumulation of fatty acids in the mouse failing heart, while AR promoted fatty acid metabolism and preserved heart function. By inhibiting PPARγ in H9c2 cells, we further found that AR could alleviate DIC by activating PPARγ to maintain fatty acid homeostasis.
Our findings imply that AR is a promising drug candidate that treats DIC by maintaining fatty acid homeostasis. More importantly, the network-based method developed here could facilitate the mechanism discovery of AR therapy and help catalyze innovation in its clinical application.
黄芪是一种广为人知的传统中药,已使用两千多年。它是治疗慢性疾病虚弱人群(如心力衰竭和脑缺血)的著名滋补品。先前的研究报道,黄芪可以支持患有阿霉素(DOX)诱导的心脏毒性(DIC)的癌症患者的“虚弱心脏”。然而,其潜在机制仍不清楚。
本研究旨在通过全面描述基于网络的关系,揭示黄芪抗DIC的关键途径和分子决定因素。
我们整合了超高效液相色谱-高分辨率质谱(UHPLC-HRMS)分析、数据库和文献检索以及人类蛋白质-蛋白质相互作用组,以发现与黄芪抗DIC相关的特定网络模块。为了验证基于网络的研究结果,我们使用了低剂量、长期DIC小鼠模型和大鼠心肌成纤维细胞H9c2。分别通过LC-MS/MS靶向分析和蛋白质印迹法定量心脏和细胞中潜在关键代谢物和蛋白质的水平。
我们构建了迄今为止描述的最全面的黄芪成分-靶点网络之一,其中包括连接64种独特成分和359个独特靶点的730种相互作用。依靠基于网络的评估,我们确定脂肪酸代谢是一个假定的关键途径,而过氧化物酶体增殖物激活受体(PPARα和PPARγ)是潜在的分子决定因素。然后我们证实,阿霉素导致小鼠衰竭心脏中脂肪酸的积累,而黄芪促进脂肪酸代谢并维持心脏功能。通过在H9c2细胞中抑制PPARγ,我们进一步发现黄芪可以通过激活PPARγ维持脂肪酸稳态来减轻DIC。
我们的研究结果表明,黄芪是一种有前途的治疗DIC的候选药物。更重要的是,这里开发的基于网络的方法可以促进黄芪治疗机制的发现,并有助于推动其临床应用的创新。